Medical Technology Veteran Michael Ryan Joins Sigyn Therapeutics Board Amid Blood Purification Technology Development

Sigyn Therapeutics (OTCQB: SIGY), a developer of blood purification technologies, has appointed Michael Ryan, a prominent figure in the medical technology industry, to its Board of Directors. Ryan, a Founding Director of Irrus Investments, Ltd., brings extensive experience in medical technology development and investment to the company at a critical phase in its development of treatments for life-threatening conditions.

The appointment is particularly significant as Sigyn Therapeutics advances its lead product, Sigyn Therapy, which has shown promise in reducing viral pathogens, bacterial toxins, and pro-inflammatory cytokines from human blood plasma. This technology could potentially address major global health challenges, including antibiotic-resistant bacterial infections and sepsis, the leading cause of death in U.S. hospitals.

Ryan's track record includes successful leadership roles as CEO of Sedana Medical until its Nasdaq First North listing in 2017 and as CEO of Artema Medical AB, which was acquired by Datascope Corporation. Through Irrus Investments, Ryan has overseen investments exceeding $50 million in 40 early-stage life science and technology companies across Ireland, UK, Sweden, and the United States.

The strategic appointment comes as Sigyn Therapeutics prepares for first-in-human studies of its technology in combination with dialysis treatments. The company's focus on extending the lives of end-stage renal disease patients could have significant implications for the dialysis industry. Additionally, Sigyn's development of oncology-focused technologies positions the company to potentially deliver strategic value to both the dialysis and biopharmaceutical sectors.